SPORE in Cervical Cancer - Project 5: A Phase I Safety and Immunogenicity Study of a HP16- Specific Therapeutic Protein, TA-CIN, Administered Intratumorally During Chemoradiation, in Patients with Inoperable HPV16+ Cervical Cancer
Our overall goal is to test whether intratumoral TA-CIN/GPI-0100 vaccination combined with chemoradiotherapy will induce HPV antigen-specific immune responses that correlate with histopathological changes in the tumor microenvironment
